nodes	percent_of_prediction	percent_of_DWPC	metapath
Topotecan—ABCG2—Dexamethasone—psoriatic arthritis	0.107	0.133	CbGbCtD
Topotecan—ABCB1—Methylprednisolone—psoriatic arthritis	0.102	0.127	CbGbCtD
Topotecan—ABCG2—Methotrexate—psoriatic arthritis	0.0861	0.107	CbGbCtD
Topotecan—ABCB1—Betamethasone—psoriatic arthritis	0.0664	0.0824	CbGbCtD
Topotecan—ABCB1—Prednisolone—psoriatic arthritis	0.0655	0.0813	CbGbCtD
Topotecan—ABCB1—Prednisone—psoriatic arthritis	0.0619	0.0768	CbGbCtD
Topotecan—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0612	0.076	CbGbCtD
Topotecan—CYP3A4—Triamcinolone—psoriatic arthritis	0.0464	0.0576	CbGbCtD
Topotecan—CYP3A4—Betamethasone—psoriatic arthritis	0.0398	0.0494	CbGbCtD
Topotecan—CYP3A4—Prednisolone—psoriatic arthritis	0.0393	0.0487	CbGbCtD
Topotecan—ABCB1—Dexamethasone—psoriatic arthritis	0.0386	0.0479	CbGbCtD
Topotecan—CYP3A4—Prednisone—psoriatic arthritis	0.0371	0.046	CbGbCtD
Topotecan—ABCB1—Methotrexate—psoriatic arthritis	0.0311	0.0385	CbGbCtD
Topotecan—CYP3A4—Dexamethasone—psoriatic arthritis	0.0232	0.0287	CbGbCtD
Topotecan—Haemorrhage—Betamethasone—psoriatic arthritis	0.000571	0.00294	CcSEcCtD
Topotecan—Haemorrhage—Dexamethasone—psoriatic arthritis	0.000571	0.00294	CcSEcCtD
Topotecan—Angiopathy—Methylprednisolone—psoriatic arthritis	0.00057	0.00294	CcSEcCtD
Topotecan—Immune system disorder—Methylprednisolone—psoriatic arthritis	0.000567	0.00292	CcSEcCtD
Topotecan—Mediastinal disorder—Methylprednisolone—psoriatic arthritis	0.000566	0.00292	CcSEcCtD
Topotecan—Weight increased—Prednisone—psoriatic arthritis	0.000565	0.00291	CcSEcCtD
Topotecan—Ill-defined disorder—Prednisolone—psoriatic arthritis	0.000553	0.00285	CcSEcCtD
Topotecan—Malnutrition—Methylprednisolone—psoriatic arthritis	0.000547	0.00282	CcSEcCtD
Topotecan—Angioedema—Prednisolone—psoriatic arthritis	0.000544	0.00281	CcSEcCtD
Topotecan—Neuropathy peripheral—Prednisone—psoriatic arthritis	0.000543	0.0028	CcSEcCtD
Topotecan—Malaise—Prednisolone—psoriatic arthritis	0.000537	0.00277	CcSEcCtD
Topotecan—Back pain—Triamcinolone—psoriatic arthritis	0.00053	0.00273	CcSEcCtD
Topotecan—Angiopathy—Betamethasone—psoriatic arthritis	0.000518	0.00267	CcSEcCtD
Topotecan—Angiopathy—Dexamethasone—psoriatic arthritis	0.000518	0.00267	CcSEcCtD
Topotecan—Ill-defined disorder—Triamcinolone—psoriatic arthritis	0.000508	0.00262	CcSEcCtD
Topotecan—Ill-defined disorder—Methylprednisolone—psoriatic arthritis	0.000507	0.00261	CcSEcCtD
Topotecan—Alopecia—Dexamethasone—psoriatic arthritis	0.000505	0.0026	CcSEcCtD
Topotecan—Alopecia—Betamethasone—psoriatic arthritis	0.000505	0.0026	CcSEcCtD
Topotecan—Discomfort—Prednisolone—psoriatic arthritis	0.000501	0.00258	CcSEcCtD
Topotecan—Angioedema—Triamcinolone—psoriatic arthritis	0.000501	0.00258	CcSEcCtD
Topotecan—Haemoglobin—Prednisone—psoriatic arthritis	0.0005	0.00258	CcSEcCtD
Topotecan—Angioedema—Methylprednisolone—psoriatic arthritis	0.000499	0.00257	CcSEcCtD
Topotecan—Haemorrhage—Prednisone—psoriatic arthritis	0.000497	0.00256	CcSEcCtD
Topotecan—Malaise—Triamcinolone—psoriatic arthritis	0.000494	0.00255	CcSEcCtD
Topotecan—Pancytopenia—Methotrexate—psoriatic arthritis	0.000493	0.00254	CcSEcCtD
Topotecan—Malaise—Methylprednisolone—psoriatic arthritis	0.000493	0.00254	CcSEcCtD
Topotecan—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.000486	0.00251	CcSEcCtD
Topotecan—Neutropenia—Methotrexate—psoriatic arthritis	0.000485	0.0025	CcSEcCtD
Topotecan—Cough—Triamcinolone—psoriatic arthritis	0.000478	0.00246	CcSEcCtD
Topotecan—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.00047	0.00242	CcSEcCtD
Topotecan—Myalgia—Triamcinolone—psoriatic arthritis	0.000466	0.0024	CcSEcCtD
Topotecan—Pneumonia—Methotrexate—psoriatic arthritis	0.000466	0.0024	CcSEcCtD
Topotecan—Arthralgia—Methylprednisolone—psoriatic arthritis	0.000465	0.0024	CcSEcCtD
Topotecan—Myalgia—Methylprednisolone—psoriatic arthritis	0.000465	0.0024	CcSEcCtD
Topotecan—Infestation NOS—Methotrexate—psoriatic arthritis	0.000463	0.00239	CcSEcCtD
Topotecan—Infestation—Methotrexate—psoriatic arthritis	0.000463	0.00239	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.000462	0.00238	CcSEcCtD
Topotecan—Ill-defined disorder—Betamethasone—psoriatic arthritis	0.000461	0.00238	CcSEcCtD
Topotecan—Ill-defined disorder—Dexamethasone—psoriatic arthritis	0.000461	0.00238	CcSEcCtD
Topotecan—Discomfort—Triamcinolone—psoriatic arthritis	0.000461	0.00237	CcSEcCtD
Topotecan—Discomfort—Methylprednisolone—psoriatic arthritis	0.00046	0.00237	CcSEcCtD
Topotecan—Angioedema—Betamethasone—psoriatic arthritis	0.000454	0.00234	CcSEcCtD
Topotecan—Angioedema—Dexamethasone—psoriatic arthritis	0.000454	0.00234	CcSEcCtD
Topotecan—Stomatitis—Methotrexate—psoriatic arthritis	0.000451	0.00233	CcSEcCtD
Topotecan—Angiopathy—Prednisone—psoriatic arthritis	0.000451	0.00232	CcSEcCtD
Topotecan—Immune system disorder—Prednisone—psoriatic arthritis	0.000449	0.00231	CcSEcCtD
Topotecan—Malaise—Dexamethasone—psoriatic arthritis	0.000448	0.00231	CcSEcCtD
Topotecan—Malaise—Betamethasone—psoriatic arthritis	0.000448	0.00231	CcSEcCtD
Topotecan—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.000447	0.0023	CcSEcCtD
Topotecan—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.000446	0.0023	CcSEcCtD
Topotecan—Infection—Triamcinolone—psoriatic arthritis	0.000444	0.00229	CcSEcCtD
Topotecan—Sweating—Methotrexate—psoriatic arthritis	0.000444	0.00229	CcSEcCtD
Topotecan—Infection—Methylprednisolone—psoriatic arthritis	0.000443	0.00228	CcSEcCtD
Topotecan—Alopecia—Prednisone—psoriatic arthritis	0.000439	0.00226	CcSEcCtD
Topotecan—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.000438	0.00226	CcSEcCtD
Topotecan—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.000437	0.00225	CcSEcCtD
Topotecan—Epistaxis—Methotrexate—psoriatic arthritis	0.000437	0.00225	CcSEcCtD
Topotecan—Paraesthesia—Prednisolone—psoriatic arthritis	0.000437	0.00225	CcSEcCtD
Topotecan—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000433	0.00223	CcSEcCtD
Topotecan—Malnutrition—Prednisone—psoriatic arthritis	0.000433	0.00223	CcSEcCtD
Topotecan—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.000432	0.00223	CcSEcCtD
Topotecan—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.000431	0.00222	CcSEcCtD
Topotecan—Myalgia—Betamethasone—psoriatic arthritis	0.000423	0.00218	CcSEcCtD
Topotecan—Myalgia—Dexamethasone—psoriatic arthritis	0.000423	0.00218	CcSEcCtD
Topotecan—Discomfort—Dexamethasone—psoriatic arthritis	0.000418	0.00215	CcSEcCtD
Topotecan—Discomfort—Betamethasone—psoriatic arthritis	0.000418	0.00215	CcSEcCtD
Topotecan—Haemoglobin—Methotrexate—psoriatic arthritis	0.000418	0.00215	CcSEcCtD
Topotecan—Pain—Prednisolone—psoriatic arthritis	0.000416	0.00214	CcSEcCtD
Topotecan—Haemorrhage—Methotrexate—psoriatic arthritis	0.000416	0.00214	CcSEcCtD
Topotecan—Pharyngitis—Methotrexate—psoriatic arthritis	0.000412	0.00213	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.000407	0.0021	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000406	0.00209	CcSEcCtD
Topotecan—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000406	0.00209	CcSEcCtD
Topotecan—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000406	0.00209	CcSEcCtD
Topotecan—Infection—Dexamethasone—psoriatic arthritis	0.000403	0.00208	CcSEcCtD
Topotecan—Infection—Betamethasone—psoriatic arthritis	0.000403	0.00208	CcSEcCtD
Topotecan—Ill-defined disorder—Prednisone—psoriatic arthritis	0.000402	0.00207	CcSEcCtD
Topotecan—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000401	0.00207	CcSEcCtD
Topotecan—Feeling abnormal—Prednisolone—psoriatic arthritis	0.000401	0.00206	CcSEcCtD
Topotecan—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000401	0.00206	CcSEcCtD
Topotecan—Anaemia—Prednisone—psoriatic arthritis	0.0004	0.00206	CcSEcCtD
Topotecan—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000399	0.00205	CcSEcCtD
Topotecan—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000398	0.00205	CcSEcCtD
Topotecan—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000398	0.00205	CcSEcCtD
Topotecan—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000397	0.00205	CcSEcCtD
Topotecan—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000397	0.00205	CcSEcCtD
Topotecan—Angioedema—Prednisone—psoriatic arthritis	0.000396	0.00204	CcSEcCtD
Topotecan—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000394	0.00203	CcSEcCtD
Topotecan—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.000393	0.00202	CcSEcCtD
Topotecan—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.000392	0.00202	CcSEcCtD
Topotecan—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.000392	0.00202	CcSEcCtD
Topotecan—Malaise—Prednisone—psoriatic arthritis	0.00039	0.00201	CcSEcCtD
Topotecan—Anorexia—Dexamethasone—psoriatic arthritis	0.000387	0.00199	CcSEcCtD
Topotecan—Anorexia—Betamethasone—psoriatic arthritis	0.000387	0.00199	CcSEcCtD
Topotecan—Urticaria—Prednisolone—psoriatic arthritis	0.000386	0.00199	CcSEcCtD
Topotecan—Fatigue—Triamcinolone—psoriatic arthritis	0.000385	0.00199	CcSEcCtD
Topotecan—Fatigue—Methylprednisolone—psoriatic arthritis	0.000385	0.00198	CcSEcCtD
Topotecan—Pain—Triamcinolone—psoriatic arthritis	0.000382	0.00197	CcSEcCtD
Topotecan—Angiopathy—Methotrexate—psoriatic arthritis	0.000377	0.00194	CcSEcCtD
Topotecan—Immune system disorder—Methotrexate—psoriatic arthritis	0.000375	0.00193	CcSEcCtD
Topotecan—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000375	0.00193	CcSEcCtD
Topotecan—Chills—Methotrexate—psoriatic arthritis	0.000373	0.00192	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.00037	0.0019	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.00037	0.0019	CcSEcCtD
Topotecan—Arthralgia—Prednisone—psoriatic arthritis	0.000369	0.0019	CcSEcCtD
Topotecan—Myalgia—Prednisone—psoriatic arthritis	0.000369	0.0019	CcSEcCtD
Topotecan—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.000368	0.0019	CcSEcCtD
Topotecan—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.000368	0.00189	CcSEcCtD
Topotecan—Alopecia—Methotrexate—psoriatic arthritis	0.000367	0.00189	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000366	0.00189	CcSEcCtD
Topotecan—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000365	0.00188	CcSEcCtD
Topotecan—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000364	0.00188	CcSEcCtD
Topotecan—Paraesthesia—Betamethasone—psoriatic arthritis	0.000364	0.00188	CcSEcCtD
Topotecan—Discomfort—Prednisone—psoriatic arthritis	0.000364	0.00188	CcSEcCtD
Topotecan—Malnutrition—Methotrexate—psoriatic arthritis	0.000362	0.00186	CcSEcCtD
Topotecan—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000358	0.00185	CcSEcCtD
Topotecan—Dyspepsia—Betamethasone—psoriatic arthritis	0.000357	0.00184	CcSEcCtD
Topotecan—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000357	0.00184	CcSEcCtD
Topotecan—Urticaria—Triamcinolone—psoriatic arthritis	0.000355	0.00183	CcSEcCtD
Topotecan—Urticaria—Methylprednisolone—psoriatic arthritis	0.000354	0.00183	CcSEcCtD
Topotecan—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000353	0.00182	CcSEcCtD
Topotecan—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000353	0.00182	CcSEcCtD
Topotecan—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000353	0.00182	CcSEcCtD
Topotecan—Decreased appetite—Betamethasone—psoriatic arthritis	0.000353	0.00182	CcSEcCtD
Topotecan—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000353	0.00182	CcSEcCtD
Topotecan—Infection—Prednisone—psoriatic arthritis	0.000351	0.00181	CcSEcCtD
Topotecan—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00035	0.0018	CcSEcCtD
Topotecan—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00035	0.0018	CcSEcCtD
Topotecan—Back pain—Methotrexate—psoriatic arthritis	0.00035	0.0018	CcSEcCtD
Topotecan—Fatigue—Dexamethasone—psoriatic arthritis	0.00035	0.0018	CcSEcCtD
Topotecan—Fatigue—Betamethasone—psoriatic arthritis	0.00035	0.0018	CcSEcCtD
Topotecan—Pain—Betamethasone—psoriatic arthritis	0.000347	0.00179	CcSEcCtD
Topotecan—Pain—Dexamethasone—psoriatic arthritis	0.000347	0.00179	CcSEcCtD
Topotecan—Nervous system disorder—Prednisone—psoriatic arthritis	0.000346	0.00179	CcSEcCtD
Topotecan—Skin disorder—Prednisone—psoriatic arthritis	0.000343	0.00177	CcSEcCtD
Topotecan—Hyperhidrosis—Prednisone—psoriatic arthritis	0.000342	0.00176	CcSEcCtD
Topotecan—Anorexia—Prednisone—psoriatic arthritis	0.000337	0.00174	CcSEcCtD
Topotecan—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.000336	0.00173	CcSEcCtD
Topotecan—Anaemia—Methotrexate—psoriatic arthritis	0.000334	0.00172	CcSEcCtD
Topotecan—Feeling abnormal—Betamethasone—psoriatic arthritis	0.000334	0.00172	CcSEcCtD
Topotecan—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.000334	0.00172	CcSEcCtD
Topotecan—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.000332	0.00171	CcSEcCtD
Topotecan—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.000332	0.00171	CcSEcCtD
Topotecan—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000329	0.0017	CcSEcCtD
Topotecan—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000329	0.00169	CcSEcCtD
Topotecan—Malaise—Methotrexate—psoriatic arthritis	0.000326	0.00168	CcSEcCtD
Topotecan—Leukopenia—Methotrexate—psoriatic arthritis	0.000324	0.00167	CcSEcCtD
Topotecan—Urticaria—Betamethasone—psoriatic arthritis	0.000322	0.00166	CcSEcCtD
Topotecan—Urticaria—Dexamethasone—psoriatic arthritis	0.000322	0.00166	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000322	0.00166	CcSEcCtD
Topotecan—Dizziness—Prednisolone—psoriatic arthritis	0.000321	0.00166	CcSEcCtD
Topotecan—Asthenia—Triamcinolone—psoriatic arthritis	0.000321	0.00165	CcSEcCtD
Topotecan—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000321	0.00165	CcSEcCtD
Topotecan—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000321	0.00165	CcSEcCtD
Topotecan—Abdominal pain—Betamethasone—psoriatic arthritis	0.000321	0.00165	CcSEcCtD
Topotecan—Body temperature increased—Betamethasone—psoriatic arthritis	0.000321	0.00165	CcSEcCtD
Topotecan—Asthenia—Methylprednisolone—psoriatic arthritis	0.00032	0.00165	CcSEcCtD
Topotecan—Paraesthesia—Prednisone—psoriatic arthritis	0.000317	0.00163	CcSEcCtD
Topotecan—Pruritus—Triamcinolone—psoriatic arthritis	0.000316	0.00163	CcSEcCtD
Topotecan—Cough—Methotrexate—psoriatic arthritis	0.000316	0.00163	CcSEcCtD
Topotecan—Pruritus—Methylprednisolone—psoriatic arthritis	0.000316	0.00163	CcSEcCtD
Topotecan—Dyspepsia—Prednisone—psoriatic arthritis	0.000311	0.0016	CcSEcCtD
Topotecan—Myalgia—Methotrexate—psoriatic arthritis	0.000308	0.00159	CcSEcCtD
Topotecan—Chest pain—Methotrexate—psoriatic arthritis	0.000308	0.00159	CcSEcCtD
Topotecan—Arthralgia—Methotrexate—psoriatic arthritis	0.000308	0.00159	CcSEcCtD
Topotecan—Decreased appetite—Prednisone—psoriatic arthritis	0.000307	0.00158	CcSEcCtD
Topotecan—Rash—Prednisolone—psoriatic arthritis	0.000307	0.00158	CcSEcCtD
Topotecan—Dermatitis—Prednisolone—psoriatic arthritis	0.000306	0.00158	CcSEcCtD
Topotecan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000306	0.00158	CcSEcCtD
Topotecan—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000305	0.00157	CcSEcCtD
Topotecan—Fatigue—Prednisone—psoriatic arthritis	0.000305	0.00157	CcSEcCtD
Topotecan—Headache—Prednisolone—psoriatic arthritis	0.000305	0.00157	CcSEcCtD
Topotecan—Discomfort—Methotrexate—psoriatic arthritis	0.000304	0.00157	CcSEcCtD
Topotecan—Constipation—Prednisone—psoriatic arthritis	0.000302	0.00156	CcSEcCtD
Topotecan—Dizziness—Triamcinolone—psoriatic arthritis	0.000296	0.00152	CcSEcCtD
Topotecan—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.000295	0.00152	CcSEcCtD
Topotecan—Dizziness—Methylprednisolone—psoriatic arthritis	0.000295	0.00152	CcSEcCtD
Topotecan—Infection—Methotrexate—psoriatic arthritis	0.000293	0.00151	CcSEcCtD
Topotecan—Feeling abnormal—Prednisone—psoriatic arthritis	0.000291	0.0015	CcSEcCtD
Topotecan—Asthenia—Betamethasone—psoriatic arthritis	0.000291	0.0015	CcSEcCtD
Topotecan—Asthenia—Dexamethasone—psoriatic arthritis	0.000291	0.0015	CcSEcCtD
Topotecan—Nervous system disorder—Methotrexate—psoriatic arthritis	0.00029	0.00149	CcSEcCtD
Topotecan—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000289	0.00149	CcSEcCtD
Topotecan—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000289	0.00149	CcSEcCtD
Topotecan—Nausea—Prednisolone—psoriatic arthritis	0.000289	0.00149	CcSEcCtD
Topotecan—Pruritus—Dexamethasone—psoriatic arthritis	0.000287	0.00148	CcSEcCtD
Topotecan—Pruritus—Betamethasone—psoriatic arthritis	0.000287	0.00148	CcSEcCtD
Topotecan—Skin disorder—Methotrexate—psoriatic arthritis	0.000287	0.00148	CcSEcCtD
Topotecan—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.000285	0.00147	CcSEcCtD
Topotecan—Vomiting—Triamcinolone—psoriatic arthritis	0.000284	0.00146	CcSEcCtD
Topotecan—Vomiting—Methylprednisolone—psoriatic arthritis	0.000284	0.00146	CcSEcCtD
Topotecan—Rash—Triamcinolone—psoriatic arthritis	0.000282	0.00145	CcSEcCtD
Topotecan—Dermatitis—Triamcinolone—psoriatic arthritis	0.000282	0.00145	CcSEcCtD
Topotecan—Anorexia—Methotrexate—psoriatic arthritis	0.000281	0.00145	CcSEcCtD
Topotecan—Rash—Methylprednisolone—psoriatic arthritis	0.000281	0.00145	CcSEcCtD
Topotecan—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000281	0.00145	CcSEcCtD
Topotecan—Urticaria—Prednisone—psoriatic arthritis	0.000281	0.00145	CcSEcCtD
Topotecan—Headache—Triamcinolone—psoriatic arthritis	0.00028	0.00144	CcSEcCtD
Topotecan—Headache—Methylprednisolone—psoriatic arthritis	0.000279	0.00144	CcSEcCtD
Topotecan—Body temperature increased—Prednisone—psoriatic arthritis	0.000279	0.00144	CcSEcCtD
Topotecan—Abdominal pain—Prednisone—psoriatic arthritis	0.000279	0.00144	CcSEcCtD
Topotecan—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000278	0.00143	CcSEcCtD
Topotecan—Diarrhoea—Betamethasone—psoriatic arthritis	0.000278	0.00143	CcSEcCtD
Topotecan—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000269	0.00139	CcSEcCtD
Topotecan—Dizziness—Dexamethasone—psoriatic arthritis	0.000268	0.00138	CcSEcCtD
Topotecan—Dizziness—Betamethasone—psoriatic arthritis	0.000268	0.00138	CcSEcCtD
Topotecan—Nausea—Triamcinolone—psoriatic arthritis	0.000266	0.00137	CcSEcCtD
Topotecan—Paraesthesia—Methotrexate—psoriatic arthritis	0.000265	0.00137	CcSEcCtD
Topotecan—Nausea—Methylprednisolone—psoriatic arthritis	0.000265	0.00137	CcSEcCtD
Topotecan—Dyspnoea—Methotrexate—psoriatic arthritis	0.000263	0.00136	CcSEcCtD
Topotecan—Hypersensitivity—Prednisone—psoriatic arthritis	0.00026	0.00134	CcSEcCtD
Topotecan—Dyspepsia—Methotrexate—psoriatic arthritis	0.00026	0.00134	CcSEcCtD
Topotecan—Vomiting—Dexamethasone—psoriatic arthritis	0.000258	0.00133	CcSEcCtD
Topotecan—Vomiting—Betamethasone—psoriatic arthritis	0.000258	0.00133	CcSEcCtD
Topotecan—Decreased appetite—Methotrexate—psoriatic arthritis	0.000257	0.00132	CcSEcCtD
Topotecan—Rash—Dexamethasone—psoriatic arthritis	0.000256	0.00132	CcSEcCtD
Topotecan—Rash—Betamethasone—psoriatic arthritis	0.000256	0.00132	CcSEcCtD
Topotecan—Dermatitis—Dexamethasone—psoriatic arthritis	0.000256	0.00132	CcSEcCtD
Topotecan—Dermatitis—Betamethasone—psoriatic arthritis	0.000256	0.00132	CcSEcCtD
Topotecan—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000255	0.00131	CcSEcCtD
Topotecan—Fatigue—Methotrexate—psoriatic arthritis	0.000255	0.00131	CcSEcCtD
Topotecan—Headache—Dexamethasone—psoriatic arthritis	0.000254	0.00131	CcSEcCtD
Topotecan—Headache—Betamethasone—psoriatic arthritis	0.000254	0.00131	CcSEcCtD
Topotecan—Asthenia—Prednisone—psoriatic arthritis	0.000253	0.00131	CcSEcCtD
Topotecan—Pain—Methotrexate—psoriatic arthritis	0.000252	0.0013	CcSEcCtD
Topotecan—Pruritus—Prednisone—psoriatic arthritis	0.00025	0.00129	CcSEcCtD
Topotecan—Feeling abnormal—Methotrexate—psoriatic arthritis	0.000243	0.00125	CcSEcCtD
Topotecan—Diarrhoea—Prednisone—psoriatic arthritis	0.000242	0.00125	CcSEcCtD
Topotecan—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.000241	0.00124	CcSEcCtD
Topotecan—Nausea—Dexamethasone—psoriatic arthritis	0.000241	0.00124	CcSEcCtD
Topotecan—Nausea—Betamethasone—psoriatic arthritis	0.000241	0.00124	CcSEcCtD
Topotecan—Urticaria—Methotrexate—psoriatic arthritis	0.000235	0.00121	CcSEcCtD
Topotecan—Dizziness—Prednisone—psoriatic arthritis	0.000234	0.0012	CcSEcCtD
Topotecan—Abdominal pain—Methotrexate—psoriatic arthritis	0.000233	0.0012	CcSEcCtD
Topotecan—Body temperature increased—Methotrexate—psoriatic arthritis	0.000233	0.0012	CcSEcCtD
Topotecan—Vomiting—Prednisone—psoriatic arthritis	0.000225	0.00116	CcSEcCtD
Topotecan—Rash—Prednisone—psoriatic arthritis	0.000223	0.00115	CcSEcCtD
Topotecan—Dermatitis—Prednisone—psoriatic arthritis	0.000223	0.00115	CcSEcCtD
Topotecan—Headache—Prednisone—psoriatic arthritis	0.000221	0.00114	CcSEcCtD
Topotecan—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000218	0.00112	CcSEcCtD
Topotecan—Asthenia—Methotrexate—psoriatic arthritis	0.000212	0.00109	CcSEcCtD
Topotecan—Nausea—Prednisone—psoriatic arthritis	0.00021	0.00108	CcSEcCtD
Topotecan—Pruritus—Methotrexate—psoriatic arthritis	0.000209	0.00108	CcSEcCtD
Topotecan—Diarrhoea—Methotrexate—psoriatic arthritis	0.000202	0.00104	CcSEcCtD
Topotecan—Dizziness—Methotrexate—psoriatic arthritis	0.000195	0.00101	CcSEcCtD
Topotecan—Vomiting—Methotrexate—psoriatic arthritis	0.000188	0.000967	CcSEcCtD
Topotecan—Rash—Methotrexate—psoriatic arthritis	0.000186	0.000959	CcSEcCtD
Topotecan—Dermatitis—Methotrexate—psoriatic arthritis	0.000186	0.000958	CcSEcCtD
Topotecan—Headache—Methotrexate—psoriatic arthritis	0.000185	0.000953	CcSEcCtD
Topotecan—Nausea—Methotrexate—psoriatic arthritis	0.000175	0.000904	CcSEcCtD
